Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
< Previous
1
2
3
4
Next >
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Elects Jacqueline Wright to Its Board of Directors
December 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
December 15, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
November 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
November 09, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
November 03, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 02, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 19, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
September 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
September 18, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
September 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
September 16, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Statement on the Passing of Two Senior Executives
September 06, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
September 01, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
August 25, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
August 16, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
August 05, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 22, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
July 08, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
June 18, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
June 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
June 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
June 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
June 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
May 26, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
May 24, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.